Soleno Therapeutics Inc Stock Price, News & Analysis

Soleno Therapeutics (NASDAQ: SLNO) announced its fourth quarter and full-year financial results for 2021. The company received FDA meeting minutes regarding data adequacy for a potential NDA submission for DCCR in treating Prader-Willi syndrome (PWS). Soleno plans to initiate a new study with currently enrolled participants. The company closed a $15 million public offering on March 31, 2022. Financially, R&D expenses were $3.8 million for Q4 2021, down from $5.6 million year-over-year, while the net loss for the year increased to $30.9 million from $24.6 million. As of December 31, 2021, cash reserves decreased to $21.3 million.

Soleno Therapeutics, Inc. (NASDAQ: SLNO) has priced a public offering of 40 million shares at $0.25 each, with 20 million pre-funded warrants at $0.24, totaling gross proceeds of approximately $14.8 million. The offering includes accompanying warrants exercisable at $0.30 per share. Proceeds will fund research on DCCR tablets for Prader-Willi Syndrome and cover general corporate purposes. The offering is set to close around March 31, 2022, subject to customary conditions. Oppenheimer & Co. Inc. is the sole book-running manager.

Soleno Therapeutics, Inc. (NASDAQ: SLNO) announced its intention to offer and sell shares of common stock and pre-funded warrants in an underwritten public offering. Each share or pre-funded warrant will be sold with an exercisable common warrant. The offering's completion and terms are subject to market conditions. Proceeds will primarily fund research and development of the DCCR tablets for Prader-Willi Syndrome, along with general corporate purposes. Oppenheimer & Co. Inc. is the sole book-running manager for this offering.

Soleno Therapeutics (NASDAQ: SLNO) announced that Running for Research - Prader-Willi Syndrome will fund a clinical study of Diazoxide Choline Extended-Release (DCCR) for early-phase Prader-Willi Syndrome (PWS) patients. The multi-center trial will involve 40 subjects at four U.S. institutions, aiming to assess DCCR's effectiveness in preventing hyperphagia progression. Initial data from ongoing Phase 3 trials indicate potential benefits of DCCR. Running for Research exceeded their funding goals significantly, reflecting strong community support for the study.

Soleno Therapeutics, Inc. (NASDAQ: SLNO), a clinical-stage biopharmaceutical company, announced its CEO Anish Bhatnagar will present a corporate overview at the BIO CEO & Investor Conference on February 15, 2022, at 2:15 PM Eastern Time. The company focuses on developing novel therapeutics for rare diseases. Its lead candidate, DCCR extended-release tablets, is in Phase 3 clinical development for treating Prader-Willi Syndrome (PWS). For more information, visit www.soleno.life.

Soleno Therapeutics (NASDAQ: SLNO) announced the grant of inducement awards to new executives, Scott Madsen and Charles Horn, each receiving non-qualified stock options for 70,000 shares. The options have an exercise price of $0.34 per share, equal to the stock's closing price on January 28, 2022. The options will vest over four years, with 25% vesting each year upon continued employment. Soleno is focused on developing therapeutics for rare diseases, with its lead product, DCCR, in Phase 3 clinical trials for Prader-Willi Syndrome.

Soleno Therapeutics (NASDAQ: SLNO), a biopharmaceutical company, updated on its progress with the FDA regarding its DCCR (diazoxide choline) extended-release tablets for treating Prader-Willi syndrome (PWS). Following a Type C meeting on December 21, 2021, the FDA showed receptiveness to a study design utilizing current participants from the ongoing Study C602 to gather additional clinical data necessary for a New Drug Application (NDA). The company plans to submit a proposal for this study soon. Currently, there are no approved therapies addressing the symptoms of PWS, underscoring the significance of Soleno’s work.

Soleno Therapeutics, Inc. (NASDAQ: SLNO) announced the participation of CEO Anish Bhatnagar in a panel discussion at the LifeSci Partners 11th Annual Corporate Access Event on January 6, 2022. The panel, titled Patient Advocacy: Honing the Skill for Crossover Communications between Patients and Stakeholders, will take place at 2:00 PM ET. A live webcast is available at this link, and a replay can be accessed on the company’s website. Soleno is focused on developing treatments for rare diseases, notably evaluating its lead candidate for Prader-Willi Syndrome.

Soleno Therapeutics (NASDAQ: SLNO) announced the grant of stock options to new VP of Clinical Development, Michael Woloschak, in compliance with Nasdaq rules.

The non-qualified stock option is for 75,000 shares at an exercise price of $0.763, equal to Soleno's stock closing price on November 16, 2021. The options vest over four years, beginning with 1/4 on the one-year anniversary of September 27, 2021, and subsequently 1/48 each month, contingent on continued employment.

Soleno focuses on developing therapies for rare diseases, including its candidate for Prader-Willi Syndrome.